Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stacy Brown

Nurse Practitioner, Family Mt Juliet, TN Nurse Practitioner

NPI 1093937872 CMS profile 10769308

325 Old Pleasant Grove Rd, Mt Juliet, TN 37122

Open in the dashboard

General payments

$719,342

1,951 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Brown of Mt Juliet, TN is reported in the CMS Open Payments database as having received $719,342 across 1,951 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $134,148 366
2024 General $166,482 392
2023 General $151,007 381
2022 General $184,832 470
2021 General $82,873 342

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Brown
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Stacy Brown were reported at $134,148. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Stacy Brown Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $82,873 $124 $35–$379 $132
2022 $184,832 $141 $44–$430 $149
2023 $151,007 $154 $49–$476 $160
2024 $166,482 $165 $51–$504 $164
2025 $134,148 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $530,889 1,226 payments
  2. AstraZeneca Pharmaceuticals LP $138,980 248 payments
  3. Novo Nordisk Inc $30,062 111 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $8,507 34 payments
  5. Esperion Therapeutics, Inc. $4,248 35 payments
  6. Corcept Therapeutics $1,868 45 payments
  7. Sanofi-Aventis U.S. LLC $754 40 payments
  8. Xeris Pharmaceuticals, Inc. $657 39 payments
  9. Abbott Laboratories $603 24 payments
  10. Amgen Inc. $562 38 payments
  11. Other $2,212 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $486,151 788 payments
  2. Travel and Lodging $212,448 280 payments
  3. Food and Beverage $20,519 878 payments
  4. Education $224 5 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $285,165 778 payments
  2. FARXIGA $138,914 244 payments
  3. TRULICITY $68,089 215 payments
  4. Ozempic $28,691 104 payments
  5. Kerendia $8,507 34 payments
  6. NEXLETOL $4,248 35 payments
  7. NEXLIZET $3,827 15 payments
  8. RYBELSUS $2,239 70 payments
  9. Korlym $1,868 45 payments
  10. JARDIANCE $644 41 payments
  11. Other $6,726 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

4,195

Median for Nurse Practitioner: 389

Drug cost

$2,465,782

Median for Nurse Practitioner: $21,885

Branded share of claims

66%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 594 $708,096
Ozempic Semaglutide Brand 306 $387,920
Tresiba Flextouch U-200 Insulin Degludec Brand 194 $249,937
Farxiga Dapagliflozin Propanediol Brand 260 $223,252
Jardiance Empagliflozin Brand 163 $157,915
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 145 $154,360
Trulicity Dulaglutide Brand 118 $141,638
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 63 $59,137
Glyxambi Empagliflozin/Linagliptin Brand 52 $52,706
Synjardy Xr Empagliflozin/Metformin Hcl Brand 31 $30,112

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$48,276

Medicare's payments for the services billed

Medicare patients

241

Average age 73

Services billed

2,522

122 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 59%
Arthritis 47%
Ischemic heart disease 36%
Depression 23%
Atrial fibrillation 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$77,272 594 —
FARXIGA
$24,076 260 —
Ozempic
$4,969 306 —
RYBELSUS
$1,384 11 —
Korlym
$1,303 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,951 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record